# GARNET

Source: https://onco.cc/trials/garnet/  
OnCo record `garnet` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GARNET showed that the PD-1 antibody dostarlimab produced lasting responses in about four in ten women with mismatch repair-deficient endometrial cancer that had returned after chemotherapy, which won the drug its first approvals.

## Summary

GARNET was a large phase 1 dose-finding and expansion study of dostarlimab, a PD-1 antibody, in advanced solid tumours. Its expansion cohorts enrolled recurrent or advanced endometrial cancer after platinum, split by mismatch repair status, and a cohort of non-endometrial mismatch repair-deficient tumours. The primary endpoints for the expansion cohorts were objective response rate and duration of response by independent review.

In the mismatch repair-deficient endometrial cohort roughly four in ten patients responded and most responses were durable, with a lower response rate in the proficient cohort. Dostarlimab received accelerated approval in the United States in April 2021 for mismatch repair-deficient recurrent endometrial cancer and later a tumour-agnostic approval for mismatch repair-deficient solid tumours; the RUBY trial then moved it into first line with chemotherapy.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-17
- Tags: subtype-trials
- Registry id: NCT02715284
- Phase: 1
- Setting: Advanced solid tumours, with expansion cohorts in mismatch repair-deficient and mismatch repair-proficient recurrent or advanced endometrial cancer after platinum chemotherapy and in other mismatch repair-deficient tumours: single-arm dostarlimab
- Sponsor: Tesaro (GSK)
- Enrolled: 729
- Result: Dostarlimab produced durable objective responses in roughly four in ten patients with mismatch repair-deficient recurrent endometrial cancer; accelerated approval in April 2021.

## Sources

- ClinicalTrials.gov NCT02715284: https://clinicaltrials.gov/study/NCT02715284

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Mismatch-repair-deficient endometrial cancer](https://onco.cc/cancers/endometrial-mmr-deficient/)
- drugs: [Dostarlimab](https://onco.cc/drugs/dostarlimab/)
- companies: [GSK](https://onco.cc/companies/gsk/)
- people: [Ana Oaknin](https://onco.cc/people/ana-oaknin/)
- key papers: [GARNET: dostarlimab in mismatch repair-deficient recurrent or advanced endometrial cancer](https://onco.cc/key-papers/paper-garnet-dostarlimab-oaknin-jama-oncol-2020/)

---
JSON: https://onco.cc/api/v1/entities/garnet.json